Skip to Content

Tag: Nasdaq

Also Noted

Viemed focuses on NASDAQ 

December 12, 2023HME News Staff

LAFAYETTE, La. - Viemed Healthcare has received approval from the Toronto Stock Exchange to voluntarily delist its common shares on the TSX, in a move that will allow the company to focus on its listing on the NASDAQ Capital Market. “The company is taking strategic action to enhance market efficiency and optimize our administrative processes by consolidating trading volumes on NASDAQ, as the majority of both outstanding shares and trading volume is currently concentrated in the United States,”...

Nasdaq, Viemed

Read Full Articlered right arrow icon

Casey Hoyt

Specialty Providers

Viemed in 'strong position'

March 3, 2023HME News Staff

LAFAYETTE, La. – Viemed Healthcare reported net revenue of $37.5 million for the fourth quarter, a 30% increase over the same quarter in 2021, and $138.8 million for full year 2022.  Net income for the quarter and year totaled $2.4 million and $6.2 million, respectively. Adjusted EBITDA totaled approximately $9.3 million and $30 million, respectively.  “Our favorable resolution of the OIG matter, debt free balance sheet and access to $90 million of additional liquidity...

Casey Hoyt, home ventilator therapy, Nasdaq, Viemed Healthcare

Read Full Articlered right arrow icon

Quipt Home Medical

Also Noted

Quipt Home Medical rings bell

September 7, 2021HME News Staff

CINCINNATI – The Quipt Home Medical team, including Greg Crawford, chairman and CEO, rang the Nasdaq opening bell on Sept. 2 in celebration of its listing on the exchange on May 27. “The Nasdaq listing is an incredible achievement for our over 600 employees and longstanding shareholders, as we continue our mission of providing superior patient care for at home respiratory patients across the United States,” Crawford said. “Joining an exchange that is home to some of the most...

Nasdaq, Quipt Home Medical

Read Full Articlered right arrow icon

Also Noted

Quipt Home Medical files form with SEC

May 17, 2021HME News Staff

CINCINNATI – Quipt Home Medical has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission, marking a significant milestone in the process of the company listing its common share on the Nasdaq. “Quipt’s rapidly growing operations are completely based in the United States, making the filing of our Form 40-F a significant steppingstone for the company,” said Greg Crawford, CEO and chairman of Quipt. “We are...

Nasdaq, Quipt Home Medical, SEC

Read Full Articlered right arrow icon

Also Noted

Protech Home Medical to change name

May 11, 2021HME News Staff

CINCINNATI – Protech Home Medical plans to change its name to Quipt Home Medical and consolidate its common shares on the basis of one post-consolidation common share for every four pre-consolidation shares, pending regulatory approvals, including TSX Venture Exchange approval. The company expects to complete the name change and consolidation on May 13, and to begin trading on the TSXV under the new symbol QIPT on that day. Protech also expects to get listed on the NASDAQ...

Nasdaq, Protech Home Medical, Quipt Home Medical, Trading

Read Full Articlered right arrow icon

Also Noted

Stockholders green light DFB, AdaptHealth merger

November 8, 2019HME News Staff

NEW YORK - DFB Healthcare Acquisitions stockholders have voted to approve all of the proposals related to its merger with AdaptHealth Holdings. The company's board of directors previously approved the combination and recommended that stockholders do the same. Stockholders also approved proposals to: change DFB's name to AdaptHealth and remove certain provisions related to DFB's status as a blank check company; issue certain securities for complying with applicable listing rules of the...

AdaptHealth, Mergers & Acquisitions (M&A), Nasdaq

Read Full Articlered right arrow icon

Also Noted

Alliqua raises $34.5M

May 5, 2015HME News Staff

LANGHORNE, Pa. - Alliqua BioMedical, a provider of advanced wound care products, has raised $34.5 million through a public offering. The company, listed on the NASDAQ as ALOA, sold about 6.6 million shares of its common stock at a price of $4.55 per share. Alliqua plans to use the net proceeds from the offering to “fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes,” according...

Alliqua BioMedical, Nasdaq, Public offering, Wound Care

Read Full Articlered right arrow icon


NASDAQ puts Inogen on notice

April 21, 2015HME News Staff

GOLETA, Calif. - Inogen has received a notice from the NASDAQ stating it's not in compliance with a rule requiring timely filing of periodic financial reports with the Securities and Exchange Commission.Inogen received the notice on April 15 after failing to file its Form 10-K for the fiscal year ended Dec. 31, 2014, on two separate occasions.“The NASDAQ notice has no immediate effect on the listing or trading of Inogen's common stock on the NASDAQ Global Select Market,” the company stated...

Documentation, Earnings, Inogen, Nasdaq, Public company

Read Full Articlered right arrow icon

Also Noted

ARI to ring NASDAQ bell

April 10, 2014HME News Staff

MILWAUKEE - ARI Network Services, provider of data-driven software tools and marketing services, will ring the NASDAQ Stock Market's closing bell April 14. “Three years ago, we implemented a plan to return to NASDAQ, and today we are honored to commemorate the achievement of re-listing by formally ringing the closing bell,” said Roy Olivier, president and CEO. ARI has seen 10 consecutive years of positive EBITDA and operating cash flows, with 95% reoccurring revenue, according to a release.

ARI Network Services, Nasdaq

Read Full Articlered right arrow icon

Also Noted

INGN opens for trading

February 18, 2014HME News Staff

GOLETA, Calif. - Inogen (INGN) opened for trading on the NASDAQ on Feb. 14, pricing about 4.4 million shares of its stock at $16 per share, the low end of an expected range of $16 to $18. On Feb. 18, the company's stock was trading at $15.28 per share. Inogen filed for an initial public offering (IPO) in November. J.P. Morgan was the sole bookrunner on the deal.

Inogen, Nasdaq, Stock